Corcept Therapeutics Incorporated

NasdaqCM:CORT Voorraadrapport

Marktkapitalisatie: US$5.9b

Corcept Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Corcept Therapeutics heeft een totaal eigen vermogen van $638.8M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $784.3M en $145.4M. De EBIT Corcept Therapeutics is $143.4M waardoor de rentedekking -6.2 is. Het heeft contanten en kortetermijnbeleggingen van $380.3M.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio-6.2x
ContantUS$380.34m
AandelenUS$638.84m
Totaal verplichtingenUS$145.42m
Totaal activaUS$784.26m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

Sep 28
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable

If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Sep 06
If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity

Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

Aug 01
Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)

With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

Apr 15
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23
After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23
Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Oct 11

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Sep 27
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $467.0M ) CORT } overtreffen de korte termijn passiva ( $126.2M ).

Langlopende schulden: De kortetermijnactiva CORT ( $467.0M ) overtreffen de langetermijnschulden ( $19.2M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: CORT is schuldenvrij.

Schuld verminderen: CORT had 5 jaar geleden geen schulden.

Schuldendekking: CORT heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: CORT heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.


Balans


Ontdek gezonde bedrijven